CLEVELAND, May 2, 2019 /PRNewswire/ -- ViewRay, Inc. VRAY today announced financial results for the first quarter ended March 31, 2019.
First Quarter 2019 Highlights:
- Received 7 new orders for MRIdian systems totaling $42.8 million, compared to 3 orders totaling $21.2 million in the first quarter of 2018.
- Total revenue of $20.3 million, primarily from 3 revenue units and 1 system upgrade, compared to $26.2 million, primarily from 4 revenue units and 1 system upgrade, in the first quarter of 2018.
- Total backlog increased to $237.5 million as of March 31, 2019, from $212.3 million as of December 31, 2018.
- Cash and cash equivalents were $145.8 million as of March 31, 2019.
"Our first quarter results are a solid start to the year and reflect progress on our commercial, innovation, and clinical pipelines," said Scott Drake, President and CEO. "We are well-positioned to execute in 2019 and are focused on becoming the standard of care in radiation oncology."
First Quarter 2019 Financial Results:
Total revenue for the three months was $20.3 million, compared to $26.2 million for the same period last year.
Total cost of revenue was $25.7 million, compared to $20.6 million for the same period last year. Total cost of revenue in the first quarter of 2019 was impacted by approximately $7.0 million of charges, primarily driven by higher than anticipated installation costs related to historical upgrade commitments. The $7.0 million includes $5.6 million of one-time charges and $1.4 million of expenses.
Total gross profit was $(5.4) million, compared to $5.6 million for the same period last year.
Total operating expenses were $25.0 million, compared to $16.9 million for the same period last year.
Net loss was $33.4 million, or $0.34 per share, compared to $7.5 million, or $0.11 per share, for the same period last year.
ViewRay had total cash and cash equivalents of $145.8 million at March 31, 2019.
Financial Guidance:
The Company is reiterating its financial guidance for the full year 2019. The Company anticipates 2019 total revenue to be in the range of $111 million to $124 million, and total cash usage to be in the range of $65-$75 million.
Conference Call and Webcast
ViewRay will hold a conference call to discuss results on Thursday, May 2, 2019 at 4:30 p.m. ET / 1:30 p.m. PT. The dial-in numbers are (844) 277-1426 for domestic callers and (336) 525-7129 for international callers. The conference ID number is 8616638. A live webcast of the conference call will be available on the investor relations page of ViewRay's corporate website at www.viewray.com.
After the live webcast, a replay of the webcast will remain available online on the investor relations page of ViewRay's corporate website, www.viewray.com, for 14 days following the call. In addition, a telephonic replay of the call will be available until May 9, 2019. The replay dial-in numbers are (855) 859-2056 for domestic callers and (404) 537-3406 for international callers. Please use the conference ID number 8616638.
About ViewRay
ViewRay®, Inc. VRAY, designs, manufactures and markets the MRIdian® radiation therapy system. MRIdian is built upon a proprietary high-definition MR imaging system designed from the ground up to address the unique challenges and clinical workflow for advanced radiation oncology. Unlike MR systems used in diagnostic radiology, MRIdian's high-definition MR was purposely built to deliver high-precision radiation without unnecessary beam distortion, and consequently, help to mitigate skin toxicity and other safety concerns that may otherwise arise when high magnetic fields interact with radiation beams. ViewRay and MRIdian are registered trademarks of ViewRay, Inc.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of Section 27A of the Private Securities Litigation Reform Act. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, the rate of new orders, upgrades and installations, ViewRay's financial guidance for the full year 2019 and ViewRay's conference call to discuss its first quarter results. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to commercialize MRIdian Linac System, demand for ViewRay's products, the ability to convert backlog into revenue, and the timing of delivery of ViewRay's products, the timing, results and other uncertainties associated with clinical trials, the ability to raise the additional funding needed to continue to pursue ViewRay's business and product development plans, the inherent uncertainties associated with developing new products or technologies, competition in the industry in which ViewRay operates and overall market conditions. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to ViewRay's business in general, see ViewRay's current and future reports filed with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the fiscal year ended December 31, 2018 and its Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2019, as updated periodically by the company's other filings with the SEC. These forward-looking statements are made as of the date of this press release, and ViewRay assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.
VIEWRAY, INC. | ||||||||
Consolidated Statements of Operations and Comprehensive Loss | ||||||||
(In thousands, except share and per share data) | ||||||||
Three Months Ended March 31, | ||||||||
2019 | 2018 | |||||||
Revenue: | ||||||||
Product | $ | 18,874 | $ | 25,379 | ||||
Service | 1,291 | 692 | ||||||
Distribution rights | 119 | 119 | ||||||
Total revenue | 20,284 | 26,190 | ||||||
Cost of revenue: | ||||||||
Product | 22,033 | 19,711 | ||||||
Service | 3,615 | 909 | ||||||
Total cost of revenue | 25,648 | 20,620 | ||||||
Gross margin | (5,364) | 5,570 | ||||||
Operating expenses: | ||||||||
Research and development | 5,031 | 3,770 | ||||||
Selling and marketing | 4,885 | 3,246 | ||||||
General and administrative | 15,109 | 9,846 | ||||||
Total operating expenses | 25,025 | 16,862 | ||||||
Loss from operations | (30,389) | (11,292) | ||||||
Interest income | 220 | 2 | ||||||
Interest expense | (759) | (1,866) | ||||||
Other (expense) income, net | (2,433) | 8,342 | ||||||
Loss before provision for income taxes | $ | (33,361) | $ | (4,814) | ||||
Provision for income taxes | — | — | ||||||
Net loss and comprehensive loss | $ | (33,361) | $ | (4,814) | ||||
Amortization of beneficial conversion feature related to Series A convertible preferred | $ | — | $ | (2,728) | ||||
Net loss attributable to common stockholders, basic and diluted | $ | (33,361) | $ | (7,542) | ||||
Net loss per share, basic and diluted | $ | (0.34) | $ | (0.11) | ||||
Weighted-average common shares used to compute net loss per share attributable to common stockholders, basic and diluted | 96,741,309 | 68,943,918 | ||||||
VIEWRAY, INC. | ||||||||
Consolidated Balance Sheets | ||||||||
(In thousands, except share and per share data) | ||||||||
March 31, 2019 | December 31, 2018 | |||||||
ASSETS | ||||||||
Current assets: | ||||||||
Cash and cash equivalents | $ | 145,797 | $ | 167,432 | ||||
Accounts receivable | 27,432 | 36,867 | ||||||
Inventory | 65,140 | 49,462 | ||||||
Deposits on purchased inventory | 7,642 | 8,142 | ||||||
Deferred cost of revenue | 4,342 | 9,736 | ||||||
Prepaid expenses and other current assets | 9,060 | 6,045 | ||||||
Total current assets | 259,413 | 277,684 | ||||||
Property and equipment, net | 15,279 | 13,958 | ||||||
Restricted cash | 1,382 | 1,933 | ||||||
Right-of-use assets | 12,055 | — | ||||||
Other assets | 1,496 | 1,395 | ||||||
TOTAL ASSETS | $ | 289,625 | $ | 294,970 | ||||
LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||
Current liabilities: | ||||||||
Accounts payable | $ | 17,891 | $ | 10,207 | ||||
Accrued liabilities | 16,207 | 9,983 | ||||||
Customer deposits | 14,905 | 19,968 | ||||||
Operating lease liability, current | 1,284 | — | ||||||
Deferred revenue, current | 10,287 | 13,731 | ||||||
Total current liabilities | 60,574 | 53,889 | ||||||
Deferred revenue, net of current portion | 5,507 | 5,744 | ||||||
Long-term debt | 55,402 | 55,364 | ||||||
Warrant liabilities | 14,872 | 11,844 | ||||||
Operating lease liability, noncurrent | 11,491 | — | ||||||
Other long-term liabilities | 303 | 820 | ||||||
TOTAL LIABILITIES | 148,149 | 127,661 | ||||||
Commitments and contingencies | ||||||||
Stockholders' equity: | ||||||||
Convertible preferred stock, par value of $0.01 per share; 10,000,000 shares authorized | — | — | ||||||
Common stock, par value of $0.01 per share; 300,000,000 shares authorized at | 959 | 952 | ||||||
Additional paid-in capital | 572,855 | 565,334 | ||||||
Accumulated deficit | (432,338) | (398,977) | ||||||
TOTAL STOCKHOLDERS' EQUITY | 141,476 | 167,309 | ||||||
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY | $ | 289,625 | $ | 294,970 | ||||
SOURCE ViewRay, Inc.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
